Cellectis to Present Data on its Allogeneic CAR T-Cell Programs at the 20th American Society of Gene & Cell Therapy Annual Meeting [EN]

Publié le 25 avril 2017 à New-York, New-York (Etats-Unis)

Retour à la liste

New York, N.Y. – April 25, 2017 – Cellectis (Alternext: ALCLS; Nasdaq: CLLS), a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells, today announced that data on its gene-edited allogeneic off-theshelf CAR T-cell immunotherapies (UCART) will be presented at the ASGCT 20th Annual Meeting. The meeting will be held from May 10th to 13th, 2017 in Washington, D.C., USA.

Oral presentation:

Development of Gene Edited Allogeneic CAR T-Cell Therapy
Philippe Duchateau, PhD. Chief Scientific Officer, Cellectis

Session: 300 - Clinical Advancement of Gene Editing-Moving New Science to the Clinic -
Organized by the Clinical Trials and Regulatory Affairs Committee

Friday, May 12, 2017 from 8:35 AM to 9:10 AM EST
Lincoln 2, 3, 4

Poster presentations:

176 - Genome-Wide Analysis of TALEN® Activity in Primary Cells
Brian Busser, Sonal Temburni, Aymeric Duclert, Philippe Duchateau and Laurent

Session: Gene Targeting and Gene Correction I
Wednesday May 10, 2017 at 5:30 PM EST
Exhibit Hall A & B South

114 - UCART22: An Allogeneic Adoptive Immunotherapy for Leukemia Targeting
CD22 with CAR T-cells

Anne-Sophie Gautron, Cécile Schiffer-Mannioui, Alan Marechal, Severine Thomas,
Agnes Gouble, Laurent Poirot, Julianne Smith

Session: Cancer-Immunotherapy, Cancer Vaccines I
Wednesday May 10, 2017 from 5:30 PM to 7:30pm EST
Exhibit Hall A & B South

372 - Manufacturing of Gene-Modified Mouse CAR T-Cells
Laurent Poirot, Brian Busser, Sonal Temburni, Philippe Duchateau

Session: Gene Targeting and Gene Correction II
Thursday May 11, 2017 from 5:15 PM to 7:15 PM EST
Exhibit Hall A & B South

For further information, please contact:

Media contacts:
Jennifer Moore, VP of Communications, 917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241,

IR contact:
Simon Harnest, VP of Corporate Strategy and Finance, 646-385-9008,

Télécharger le PDF